The US Food and Drug Administration (FDA) is working to reduce drug-induced liver damage with an initiative targeting the use of acetaminophen—the most common cause of such adverse events. The agency also is promoting research on genetic factors that may contribute to drug-related liver problems.
Drug-induced liver failure is a growing concern for the FDA. Cases of acute liver failure reported to the agency's Adverse Events Reporting System (AERS) have increased from 89 in 1995 to 404 in 2005, and acetaminophen is the drug most commonly implicated in such reports.
Kuehn BM. FDA Focuses on Drugs and Liver Damage. JAMA. 2009;302(4):369–371. doi:10.1001/jama.2009.1019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: